| Unique ID issued by UMIN | UMIN000062139 |
|---|---|
| Receipt number | R000070352 |
| Scientific Title | Clinical trial of ultra-hypofractionated small pelvic irradiation for cervical cancer using online adaptive radiotherapy with MR linac |
| Date of disclosure of the study information | 2026/07/04 |
| Last modified on | 2026/07/04 17:22:36 |
Clinical trial of ultra-hypofractionated small pelvic irradiation for cervical cancer using online adaptive radiotherapy with MR linac
Clinical trial of ultra-hypofractionated radiotherapy for cervical cancer using MR linac
Clinical trial of ultra-hypofractionated small pelvic irradiation for cervical cancer using online adaptive radiotherapy with MR linac
Clinical trial of ultra-hypofractionated radiotherapy for cervical cancer using MR linac
| Japan |
Cervical cancer
| Radiology |
Malignancy
NO
To investigate the safety and efficacy of ultra-hypofractionated small pelvic irradiation for cervical cancer using online adaptive radiotherapy with MR linac.
Safety,Efficacy
The 2-year pelvic control
The 2-year local control, the 2-year progress-free survival, acute toxicity, late toxicity
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Device,equipment |
Small pelvic irradiation with 30 Gy in 5 fractions using MR linac (twice a week).
| 20 | years-old | <= |
| Not applicable |
Female
(1) Cervical cancer stage IB1-2, stage IIA1 (FIGO2018) without corpus invasion, for which curative radiation therapy is planned, or cases with a moderate risk of postoperative recurrence (for cases without lymph node dissection, the preoperative tumor diameter must be less than 4 cm).
(2) Histologically proven squamous cell carcinoma.
(3) 20 years or older (at registration).
(4) ECOG PS of 0-2
(5) No prior history of radiation therapy to the abdomen or pelvis.
(6) Adequate organ functions
(7) Written informed consent
(1) Patients with severe complications (heart failure, renal failure, hepatic failure, respiratory dysfunction, lymphatic obstruction, poorly controlled diabetes, etc.).
(2) Patients with metal implants that are not compatible with MRI.
(3) Patients who have difficulty maintaining a supine position due to claustrophobia, etc.
(4) An infectious disease (excluding viral hepatitis) that requires systemic treatment
(5) Other active malignancy at the start of our study
(6) Patients requiring systemic steroids medication or other immunosuppressants
(7) Women who are pregnant, possibly pregnant, within 28 days postpartum, or breastfeeding.
(8) Patients with severe psychological disorder
(9) Other cases that were judged to be inappropriate for conducting this study
25
| 1st name | Rei |
| Middle name | umezawa |
| Last name | Umezawa |
Tohoku University Hospital
Department of Radiation Oncology
980-8574
1-1 Seiryo-machi, Aoba-ku, Sendai
022-717-7312
reirei513@hotmail.com
| 1st name | Rei |
| Middle name | umezawa |
| Last name | Umezawa |
Tohoku University Hospital
Department of Radiation Oncology
980-8574
1-1 Seiryo-machi, Aoba-ku, Sendai
022-717-7312
reirei513@hotmail.com
Tohoku University
Grant-in-Aid for Scientific Research (C)
Japanese Governmental office
Ethics Committee Tohoku University Hospital
1-1 Seiryo-machi, Aoba-ku, Sendai
022-728-4105
ec@rinri.hosp.tohoku.ac.jp
NO
| 2026 | Year | 07 | Month | 04 | Day |
Unpublished
Preinitiation
| 2026 | Year | 05 | Month | 07 | Day |
| 2026 | Year | 08 | Month | 01 | Day |
| 2031 | Year | 03 | Month | 31 | Day |
| 2026 | Year | 07 | Month | 04 | Day |
| 2026 | Year | 07 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070352